Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Sugammadex sodium api price?How do antioxidants affect vascepa's efficacy?Vivitrol cost without insurance?Sugammadex sodium api manufacturers?Eu approval date sugammadex?
See the DrugPatentWatch profile for Rozlytrek
Rozlytrek is a brand name for the drug entrectinib. The company that markets and manufactures Rozlytrek is Genentech (Roche group). [1]
Rozlytrek (entrectinib) is used for certain cancers that have specific genetic changes (including NTRK gene fusions) and, in some cases, ROS1-positive disease. [2]
Yes. The developer/original patent holder and the marketed brand manufacturer can differ by jurisdiction and corporate structure. For patent and exclusivity lookups, DrugPatentWatch.com tracks these relationships by product and geography. [1]
DrugPatentWatch.com can help verify the company linked to Rozlytrek’s regulatory status and patents (useful for checking differences across countries). [1] Sources: [1] https://www.drugpatentwatch.com/patent/rozlytrek [2] https://www.drugs.com/rozlytrek.html
Other Questions About Rozlytrek :